ArticleOncology letters2019
Association of miR-100 expression with clinicopathological features and prognosis of patients with lung cancer.
Article in Oncology letters, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 10 citations in OpenAlex.
- Review
- Long non-coding RNA HAGLROS promotes the development of diffuse large B-cell lymphoma via suppressing miR-100.Journal of clinical laboratory analysis · 2022Article
- Prognostic value of microRNA-4521 in non-small cell lung cancer and its regulatory effect on tumor progression.Open medicine (Warsaw, Poland) · 2021Article
- Overexpression of miR-518b in non-small cell lung cancer serves as a biomarker and facilitates tumor cell proliferation, migration and invasion.Oncology letters · 2020Article
- microRNA-100 functions as a tumor suppressor in non-small cell lung cancer via regulating epithelial-mesenchymal transition and Wnt/β-catenin by targeting HOXA1.Thoracic cancer · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The expression of microRNA (miR)-100 in non-small cell lung cancer (NSCLC) and its association with clinicopathological features and poor prognosis were investigated. A total of 283 patients with NSCLC were enrolled in The First Hospital of Jiaxing from February 2013 to April 2015. Total RNA was extracted from cancer tissues and corresponding adjacent normal tissues. The expression of miR-100 was detected by RT-qPCR. Association between the expression level of miR-100 with clinicopathological features and prognosis of NSCLC were analyzed. The expression level of miR-100 in NSCLC tissues was lower than that in the normal tissues (P<0.05). According to the median expression level of miR-100 in cancer tissue, patients were divided into the high expression and low expression groups. Cross-tabulation analysis showed that the expression level of miR-100 was significantly associated with patients' age, TNM stage, metastasis and histological type (P<0.05), but not with sex (P>0.05). The proportion of patients with low miR-100 expression was higher in patients who died than in those who survived (P<0.05). Univariate prognostic analysis showed that miR-100 expression, age, TNM staging, and metastasis may be risk factors for poor prognosis in patients with NSCLC. Cox multivariate regression analysis showed that the downregulated miR-100 expression, advanced TNM stage, and metastasis were independent risk factors for poor prognosis of NSCLC. The relatively low expression level of miR-100 in NSCLC is associated with poor prognosis of patients. Therefore, miR-100 shows potential as a prognostic marker for NSCLC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.